• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

    Insmed Appoints Drayton Wise as Chief Commercial Officer

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos

    Aptamer Group and PinotBio Extend Collaboration Agreement

    Selecting a CMO Partner for Sterile Injectable Manufacturing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Alcami

    IDT Biologika

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Alcami

    IDT Biologika

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    A Brave New World of Data Integrity

    How modern CMOs are keeping up with stringent regulatory guidelines by embracing advanced laboratory information systems.

    A Brave New World of Data Integrity
    Related CONTENT
    • Asymchem
    • Mogene
    • Vetio Animal Health
    • The 20th Annual Salary Survey
    • Serialization and the Rest of Us
    Bob Voelkner, VP Sales and Marketing, LabVantage06.13.19
    It’s a good time to be a contract manufacturing organization (CMO). Pharmaceutical and biotechnology companies, in a race to stay competitive and impact more patients, are choosing to focus heavily on research and development activities, with little left over for on-premise manufacturing. This means that CMOs are in high demand, and the products they’re manufacturing are more diverse and complex than ever.

    This wave of opportunity has ushered with it an era of heightened regulatory scrutiny, particularly in relation to data integrity. The manual record-keeping practices that once satisfied regulators simply aren’t keeping up. Today’s auditors, sensitive to a recent uptick in infractions, expect broader access and more transparency from CMOs, with a particular emphasis on changes made in temporary memory.

    In order to withstand this intensifying pressure while improving operational efficiencies, CMOs large and small are sunsetting their traditional data management workflows in favor of digital tools specially designed to ensure that data are complete, consistent, enduring, and available.

    The pressure is on
    In 2016, after reporting an overall increase in offenses related to poor data management practices and inconsistent documentation, the U.S. Food and Drug Administration (FDA) issued its Data Integrity and Compliance with CGMP Guidance for Industry. The European Medicines Agency (EMA), the UK Medicines and Healthcare Products Regulatory Agency (MHRA), and the World Health Organization (WHO) also issued new or updated guidelines during this period. Under the auspices of 21 CFR 11 and Annex 11, these updates reflect a notably higher standard of quality for the practices governing data integrity in QC and manufacturing labs.

    In order to meet this elevated standard, CMOs around the world are rallying behind the principle that all data should be attributable, legible, contemporaneous, original, and accurate (qualities known by the acronym ALCOA), as well as consistent, available, enduring, and complete (ALCOA+). The concepts captured by that appended “plus” symbol are about giving a datum context, especially during future reviews and audits. In other words, ALCOA+ sets an expectation that CMOs can and will disclose a complete picture of data throughout its entire lifecycle.

    As part of this expectation, the FDA has swung its spotlight toward a concept that, until relatively recently, had been widely accepted in the industry: the idea that data isn’t really data until and unless it’s saved. That moment—an analyst clicks “Save,” committing a datum to durable media—is the bright line dividing “temporary” from “enduring.” In its temporary state, data can be manipulated multiple times, either accidentally or (in rare cases) intentionally, since it has not been committed to durable media. A mistype can be fixed, a value corrected, or, as regulators fear, a noncompliant result deliberately changed in order to meet specifications, all without detection. As long as an audit only reveals the “enduring” state, regulators worry that an important piece of the story—a piece that could reveal bad behavior or a dangerous oversight—is missing. In order to strengthen the audit trail and encourage the retention of all necessary information, the FDA and other agencies around the world now recommend that CMOs capture all data, including data that has been entered but not saved.

    This principle of dynamic auditing—that is, tracking changes to temporary data—has become a cornerstone theme of modern integrity standards, and it’s driving significant change in the way that CMOs manage their data.

    What’s at stake for the CMO?
    This world of greater data integrity, in which all activity in a dataset is subject to inspection, brings with it the possibility of severe consequences for those who are unable or unwilling to adapt.

    When an infraction is discovered, regulators typically begin by issuing warning letters and Form 483 citations. If caught in the cross-hairs of such a warning, CMOs, already under pressure to narrow their margins as much as possible, can face costly fines with devastating consequences to their bottom line. They may even be placed under a consent decree, which could prohibit them from manufacturing, holding or distributing products until they achieve regulatory compliance. Rebounding from such an injunction can be very difficult.

    Consent decrees are rare. But even a warning letter can trigger a negative spiral for CMOs, who operate in a competitive world where new business is often won and lost on the strength of reputation. A CMO carrying a data integrity infraction on its record is a CMO with diminished hope of survival.

    Even in scenarios where data management is sub-par but not subject to official sanctions, CMOs face expensive consequences. For example, if the amount of product in a bottle relies on potency, an incorrect potency value could cost the company money when a bottle is overfilled (contributing to a reduced yield) or not filled enough (making it necessary to reprocess products). These mistakes accumulate quickly, often with significant financial fallout.

    Staying out of trouble and maintaining a polished reputation are, of course, important. But for all responsible CMOs, protecting consumer health is what matters most of all, and intensified data integrity standards are, after all, designed to service the safety, efficacy, and quality of the world’s pharmaceutical supply. By maintaining compliance, CMOs aren’t just ensuring their own longevity in the marketplace; they’re also preserving product quality and availability for the patients who rely on their output.  

    In order to maintain compliance while preserving this level of supreme quality and product consistency, many CMOs are modernizing their data-related practices with the introduction of advanced laboratory information management systems (LIMS).

    What the modern CMO knows about LIMS
    Manual, paper-based record-keeping, once the mainstay of CMOs, is facing obsolescence. More and more labs are migrating away from the porous nature of this traditional approach, in which integrity is lost with each transcription error, each small deviation in standard procedure, each frog-leap from one siloed system to another.

    Efficiency is lost in traditional systems, too. Each manual task takes time. Time, especially in a market defined by tight margins and close competition, is money. Without improvements to their operational efficiency—and with their data subject to the errors and inconsistencies of manual record-keeping—CMOs risk falling behind their competitors. To avoid this fate, many CMOs are embracing an advanced generation of software-enabled electronic platforms to govern their data collection practices.

    CMOs aren’t alone in their mass migration away from manual tasks. In all areas of manufacturing, from pharmaceutical labs to car assembly plants, companies are using programmable software to take over the tasks that humans aren’t especially good at (or inclined to do). The result is a tech-enabled workflow that’s many times as efficient, and far more consistent, than a manual approach. Think of industrial automation, for example: guided by software that never deviates from its preconfigured objective, a robotic arm can screw eight thousand nuts onto eight thousand bolts with total consistency. Each nut will be turned the same number of revolutions, with the same torque, producing the same verifiable result every time. Not so in the hands of even the most diligent human worker.

    In a CMO, this level of stability and consistency begins with the adoption of a LIMS platform. The robotic arm that never stops working on the factory floor becomes the database that never stops refreshing itself in the LIMS-enabled CMO. This allows analysts to displace the burden of diligent, consistent record-keeping onto a system far more suited to its granularity and complexity, and far more resistant to error.

    LIMS pull in data automatically, through mobile devices, hand-held scanners and lab instrumentation that interfaces directly with the software, signaling the end of a problematic era in which analysts transcribed data by hand from instrument readouts, or observed and recorded test results themselves. It also introduces a new layer of impartiality in a CMO’s record-keeping system, because LIMS possess none of the complicated moral ambiguity that, in humans, can very occasionally lead to “creative” record-keeping. By contrast, a LIMS platform is neutral, inexhaustible, and fanatically consistent.

    How LIMS improves overall data management
    Purpose-built to meet specific lab functions, a LIMS platform offers what manual systems never could: a way to capture, organize, and analyze data consistently, automatically, and across multiple sites. Every activity benefits from this level of automation. Undertaking a routine workflow, for example, would once have required lab workers to interpret and follow paper-based protocols. Like 10 different chefs following the same recipe in 10 different kitchens, this would naturally lead to inconsistencies in execution—10 different cakes.

    Not so with a LIMS platform in place, which enforces consistency, and even interfaces directly with lab instrumentation to ensure it’s precisely configured according to specific assay parameters. The result is a consistent and reproducible workflow, with a predictable result, time after time.

    In an era when many CMOs are growing their global footprint through acquisition, this enforced consistency is especially valuable. Centrally hosted and globally accessible to authorized users, a LIMS platform offers the secure accessibility that geographically diverse sites need. It enforces process. It upholds standardization. And because it can pull data directly from connected instruments without relying on the accuracy of manual transcription, it provides continuous protection against quality-related risks.

    The ubiquity of a well-deployed LIMS platform helps not just in connecting remote sites, but in connecting diverse functions, too. Some advanced LIMS allow users to turn on Electronic Laboratory Notebook (ELN) and Laboratory Execution System (LES) functionality. In a traditional workflow, data would have to jump between these different systems via a paper-based chain of custody. Each jump would introduce a new possibility for error. In a modern LIMS platform, which integrates ELN and LES functions in a single uninterrupted workflow, each datum is stored exactly once and shared across the whole system. Fewer jumps, fewer opportunities for error.

    Such a high degree of integration also introduces new and in-depth searchability across complex CMO networks. With fewer siloes barricading data in fragmented clusters, and greater transparency throughout every step in a workflow, CMOs can locate and recall a detailed history of each event, whether from last month or last year. And because users interact with the LIMS platform under unique and authenticated identifiers, lab managers know with precision who entered what datum, and when. This means that they can track any irregular activities—like multiple repetitions of the same test—with a high degree of transparency, further ensuring regulatory compliance.

    Ensuring no data is forgotten
    While one of the greatest advantages of the LIMS platform is its ability to interface directly with instrumentation, every CMO still requires some degree of manual data capture, depending on the interoperability of a lab’s incumbent systems and instruments. In this case, too, the LIMS platform is invaluable as a vigilant partner for the human worker. For example, CMOs can configure their LIMS to recognize an accidental keystroke or a dropped digit. This means that users will get a prompt if, say, they’ve entered an “impossible” datum, like a pH value of 15 or a negative value for weight. Before they can proceed to their next step, they must correct that error, which helps to protect the database from inconsistencies.

    Such manual corrections are, of course, the stuff of temporary data, now within the purview of regulatory oversight. The most advanced LIMS platforms play a crucial role here, too. They’re designed to automatically capture any datum entered but not saved, and to require a reason for any changes made in temporary memory. Some LIMS even include a visual flag in the permanent data trail, signalling the presence of underlying temporary data available for review.

    The result is a clean, transparent, GxP-compliant audit trail based on the full history of a test.

    Conclusions
    As the pharmaceutical and biotechnology industries race to develop ever more advanced and complex chemical entities, pressure is growing on individual CMOs to operate more productively, cost-effectively, and safely than the next competitor. Watching over this crowded landscape is the ever-widening aperture of the industry’s regulatory alphabet: the FDA, the EMA, the MHRA, and the WHO. Their guidelines for data integrity, newly refreshed for the modern world of data collection, demand more transparency and accuracy than ever before.
    As these pressures accumulate, modern CMOs must abandon their traditional, paper-based record-keeping practices in favor of preconfigured, pre-validated LIMS built specifically for the needs of today’s pharmaceutical manufacturers. 


    Bob Voelkner is vice president of sales and marketing, Americas, LabVantage Solutions.
    Related Searches
    • contract manufacturing organization
    • it
    • cGMP
    • CMO
    Suggested For You
    Asymchem Asymchem
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    The 20th Annual Salary Survey The 20th Annual Salary Survey
    Serialization and the Rest of Us Serialization and the Rest of Us
    FDA Inspection of Asymchem Dunhua 1 API Manufacturing Facility is Successful FDA Inspection of Asymchem Dunhua 1 API Manufacturing Facility is Successful
    Central Pharma Partners with Veratrak Central Pharma Partners with Veratrak
    FDA Approves TraceLink DSCSA Pilot Submission for Network Solutions FDA Approves TraceLink DSCSA Pilot Submission for Network Solutions
    Nitrosamines Nitrosamines
    Process Validation in Biologics Development Process Validation in Biologics Development
    WuXi Biologics Completes First FDA Routine GMP Inspection WuXi Biologics Completes First FDA Routine GMP Inspection
    Pii Receives EIR From FDA Pii Receives EIR From FDA
    WuXi AppTec Testing Facilities Complete Inspections WuXi AppTec Testing Facilities Complete Inspections
    2019 Trends & Predictions 2019 Trends & Predictions
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL

    Related Content

    • Asymchem

      Asymchem

      ...
      Mandy Boyd, Asymchem 12.01.20

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19


    • The 20th Annual Salary Survey

      Plus: packaging trends, data integrity, serialization, ADCs and expediting clinical development
      Tim Wright, Editor 06.13.19

    • Serialization
      Serialization and the Rest of Us

      Serialization and the Rest of Us

      Small and mid-size manufacturers achieving post-deadline DSCSA compliance.
      Angela Holley, Business Development Director, WDPrx - Woodfield Pharmaceutical, LLC 06.13.19

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Lonza Invests In Additional Inhalation Capabilities In Tampa | Contract Pharma
      Breaking News
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      • Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      • Insmed Appoints Drayton Wise as Chief Commercial Officer
      • Clinigen Expands U.S. Site Capacity
      • Corealis CDMO Completes Deal with ArchiMed
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Pediatric Medical Device Competition Reveals Five Finalists
      Medical Device Packaging Market to Reach $34B by 2027
      Penumbra Secures CE Mark for its Advanced Mechanical Thrombectomy Tech
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      TikToker Abbie Herbert, Founder of Personal Care Brand Pavot, Launches Body Water, Razor Burn Treatment Pads With Beaubble Partnership
      E.l.f. Cosmetics Introduces ‘Big Mood Pride Mascara’ Ahead of Pride Month
      Ink World

      Latest Breaking News From Ink World

      Epson Introduces Two New SurePress Digital Label Presses
      Flint Group Flexible Packaging Europe Implements Further Price Increase
      Nazdar Launches 205 Series Inks for Roland TrueVIS SG2 and VG2 Series Printers
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Emovi, Geneva Foundation Providing Knee Treatment Tech to U.S. Army
      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      InnovationLab Acquires Flexible Printed Battery Technology from Evonik
      Canatu Receives IATF 16949:2016 Certification
      Applied Materials Announces 2Q 2022 Results

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login